CAMBRIDGE, Mass., May 31, 2022 – BlueRock Therapeutics LP, a medical phase biopharmaceutical business and wholly-owned subsidiary of Bayer AG, revealed the conclusion of registration of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic nerve cells in clients with Parkinson’s illness (PD). The function of the Ph1 medical trial is to examine the security, tolerability, and initial effectiveness of BRT-DA01 in clients with Parkinson’s illness.
“Patients with Parkinson’s illness are confronted with life altering difficulties and unpredictabilities that are not dealt with by present treatments,” stated Ahmed Enayetallah, M.D., Ph.D., Senior Vice President, Clinical Development, BlueRock Therapeutics. “We are delighted that our Phase 1 medical trial has actually finished registration and think it is an important next action towards the advancement of an unique cell treatment that has the prospective to change the treatment landscape for this ravaging illness.”
About the BRT-DA01 Phase 1 Trial
The main goal of the Ph1 trial is to examine the security and tolerability of BRT-DA01 hair transplant at 1 year post-transplant. The secondary goals of the trial are to evaluate the proof of transplanted cell survival and motor impacts at one- and two-years post-transplant, to assess ongoing security and tolerability at 2 years, and to evaluate expediency of hair transplant.
In the United States, the trial was started at Weill Cornell Medicine with Dr. Harini Sarva, M.D. as the Principal Investigator (PI) and very first surgical treatments being carried out by Dr. Viviane Tabar, Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer. Extra Neurology websites were included at the University of California, Irvine, under the assistance of Dr. Claire Henchcliffe, M.D., D.Phil., F.A.A.N., F.A.N.A. (PI), and at the University Health Network (UHN), under the assistance of Dr. Lozano, O.C., M.D., Ph.D., F.R.C.S.C., F.R.S.C., F.C.A.H.S. (PI) and Dr. Alfonso Fasano, M.D., PhD., Chair in Neuromodulation and Multi-Disciplinary Care, UHN and UoT.
More info about the Phase 1 trial is readily available at
clinicaltrials.gov
(NCT # 04802733)
As a next action, BlueRock Therapeutics prepares to start an international non-interventional research study in the 2nd half of 2022.
More details about the non-interventional research study is offered at
clinicaltrials.gov
(NCT # 05363046)
About Parkinson’s Disease
Parkinson’s illness is a progressive neurodegenerative condition triggered by afferent neuron damage in the